RxDoctor Payments Data

Dennis Unks, MD

Cardiovascular Disease · Erie, PANPI 1023014149

Payments from drug & device makers

What this record shows

Medtronic accounts for 60.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $1,213 and has fallen 97.0% since, to $36 in 2025.

$2,050in general payments, 2019–2025

Across 31 payments — averaging $66.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Boehringer Ingelheim$336
  • Impulse Dynamics (USA) Inc.$119
  • Novartis$75
  • Biosense Webster, Inc.$72
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$55
  • plus $159 from 5 others
$231,753in research payments, 2019–2025

Across 24 payments — averaging $9656.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$118K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$49K
  • Boehringer Ingelheim International GmbH$48K
  • AstraZeneca$17K

What the payments were for

  • Travel & lodging$1,02850%
  • Food & beverage$1,02150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,050 in reported general payments places this provider in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$91,307
Medicare patients
1,496
Services billed
2,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$41,381
EntrestoSacubitril/Valsartan40$36,273
JardianceEmpagliflozin23$26,413
Rosuvastatin Calcium173$2,509
Atorvastatin Calcium124$1,446
Metoprolol Succinate130$1,285
Bumetanide32$885
ClopidogrelClopidogrel Bisulfate67$779
Losartan Potassium99$734
Carvedilol74$702
Prasugrel Hcl12$642
Amlodipine Besylate85$472
Nitroglycerin36$444
Isosorbide Mononitrate ErIsosorbide Mononitrate25$353
Potassium Chloride32$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$41,38142 claims
NovartisEntresto$75$36,27340 claims
Boehringer IngelheimJardiance$336$26,41323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →